SCOTTSDALE, Ariz., Oct. 10, 2024 /PRNewswire/ -- Cyber Enviro-Tech Inc. (CETI) (OTCQB: CETI) CETI, is pleased to announce a partnership with its shareholder-based subsidiary, CETI Axenic (CAX), to pursue opportunities in the commercial laundry business. This industry, which consumes over 1.7 trillion gallons of water annually at a cost exceeding $3.5 billion, currently recycles only about 32% of the water used. With CETI's innovative water remediation systems, recycling rates can increase to over 90%, resul ...

Core Insights - LIfT BioSciences has been awarded a $300,000 G-Rex Grant to establish clinical manufacturing for its Neutrophil only Leukocyte Infusion Therapy (N-LIfT) platform, which is set to enter clinical trials [1][2] - The G-Rex manufacturing platform is designed to enhance the efficiency and scalability of cell therapy production, with LIfT aiming to utilize it to develop Immunomodulatory Alpha Neutrophils (IMANs) that target solid tumors [2][3] - ScaleReady's G-Rex Grant Program is a $20 million initiative aimed at advancing cell and gene-modified cell therapy development, providing grants and access to a consortium of partners for support [3][6] Company Overview - LIfT BioSciences is a UK and Ireland-based biotech company focused on developing a first-in-class alpha neutrophil cell therapy that addresses treatment resistance in solid tumors [4] - The company is working on engineered CAR IMAN cell therapies in collaboration with pharmaceutical partners to target various solid tumors [5] - ScaleReady provides a G-Rex-centric manufacturing platform that supports the development and manufacturing of cell and gene-modified therapies, currently utilized by over 800 organizations [6][7] Collaborations and Technology - Wilson Wolf Manufacturing, a co-inventor of the G-Rex platform, is collaborating with LIfT to create a scalable manufacturing process for N-LIfT [2][7] - Bio-Techne Corporation is partnering with Wilson Wolf to develop tailored products for G-Rex Bioreactors, enhancing the manufacturing process [8] - CellReady LLC specializes in G-Rex-based contract development and manufacturing, supporting the commercialization of cell and gene-modified therapies [9]

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of a $200,000 G-Rex Grant to Dr. Eric Tran for the development of a novel KRAS-targeted TCR-T cell therapy [1][2] Company and Industry Overview - The G-Rex Grant will significantly reduce costs associated with bringing the next generation TCR-T cell therapy into clinical trials, specifically targeting solid tumors in a Phase 1/1b clinical trial [2] - Dr. Tran aims to optimize the manufacturing process by reducing duration and implementing fully-closed system G-Rex bioreactors, utilizing Bio-Techne's GMP cytokines tailored for efficient manufacturing [3] - ScaleReady's G-Rex Grant Program is a $20 million initiative aimed at advancing cell and gene-modified cell therapy (CGT) development, offering individual grants up to $300,000 [4] - The G-Rex manufacturing platform is currently utilized by over 800 organizations, producing drug products for approximately 50% of CGT clinical trials and five commercially approved CGT drugs [5] - Companies leveraging ScaleReady's expertise can expect to save significant time and costs in the commercialization of CGT [6] - Wilson Wolf is focused on simplifying CGT therapy research and manufacturing through its scalable G-Rex technology, which is widely used in various CGT applications [7] - Bio-Techne Corporation provides innovative tools and reagents for research and clinical diagnostics, partnering with Wilson Wolf to create products tailored for G-Rex Bioreactors [8] - CellReady is the first G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based CGT development and manufacturing [9]

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of a $300,000 G-Rex Grant to Dr. Christopher A. Klebanoff for the development of a novel CD8α/β armored TCR-T cell therapy targeting a specific neoantigen in a Phase 1 clinical trial [1][2][3] Company and Industry Overview - The G-Rex Grant aims to facilitate process development, IND-enabling studies, and support clinical manufacturing for the TCR-T cell therapy, which is designed to target specific cancer cell antigens [1][3][4] - The G-Rex Grant Program is a $20 million initiative to advance cell and gene-modified cell therapy (CGT) development and manufacturing, providing individual grants up to $300,000 [8] - ScaleReady's G-Rex manufacturing platform is utilized by over 800 organizations and is involved in approximately 50% of CGT clinical trials, as well as five commercially approved CGT drugs [9] - Bio-Techne is collaborating with Wilson Wolf to create tailored products for G-Rex Bioreactors, enhancing the efficiency of reagent preparation in GMP manufacturing settings [11]

Core Viewpoint - Alpha Pro Tech, Ltd. has authorized a $1.0 million expansion of its existing share repurchase program, bringing the total available for repurchase to approximately $1.5 million [1][2]. Group 1: Share Repurchase Program - The company now has $1.5 million available for share repurchase, which includes $0.5 million remaining from a previous expansion announced in April 2024 [2]. - Management plans to repurchase shares through open market purchases or privately-negotiated transactions, with the intention to retire all shares purchased [3]. - Open market purchases may be executed through a pre-arranged repurchase plan in accordance with specific guidelines under the Securities Exchange Act of 1934 [3]. Group 2: Company Overview - Alpha Pro Tech, Ltd. is a leading manufacturer of protective apparel and building products, with operations in Nogales, Arizona, Valdosta, Georgia, and a joint venture in India [4]. - The company develops and markets disposable and limited-use protective apparel for various markets, including industrial, clean room, medical, and dental sectors [4].

ST. PAUL, Minn., Sept. 18, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that ImmunoScape Pte. Ltd. (a Singapore-U.S. based TCR-T therapy company) has been awarded a G-Rex® Grant. ImmunoScape's $250,000 G-Rex® Grant will enable process development and IND enabling studies of their novel WT1-targeted TCR-T cell therapy. "We are thankful for ScaleReady's G-Rex Grant Program and are grateful to receive an ...

ST. PAUL, Minn., Aug. 27, 2024 /PRNewswire/ -- ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) and CellReady™, today announced that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine's Laboratory for Cell and Gene Medicine (LCGM), has been awarded the inaugural G-Rex® Grant. Dr. Feldman's $300,000 G-Rex Grant will enable expeditious development of Stanford Medicine's LCGM's G-Rex platform for CAR-T cell therapy manufacturing, which w ...

Record second quarter net revenue of $193 million, up 27% year-over-year Record second quarter adjusted EBITDA of $62 million, up 49% year-over-year Record second quarter net income of $45 million, up 52% year-over-year, and record second quarter adjusted net income of $51 million, up 58% year-over-year Record first half net operating cash flow of $105 million and free cash flow of $104 million Announces Ido Bachelet as Chief Science Officer NEW YORK, Aug 7, 2024 /PRNewswire/ -- ODDITY Tech Ltd. (NASDAQ: OD ...

Bio-Techne Corporation (NASDAQ:TECH) Q4 2024 Earnings Conference Call August 7, 2024 9:00 AM ET Company Participants David Clair – Vice President-Investor Relations Kim Kelderman – President and Chief Executive Officer Jim Hippel – Chief Financial Officer Conference Call Participants Puneet Souda – Leerink Partners Jacob Johnson – Stephens Dan Arias – Stifel Dan Leonard – UBS Jack Meehan – Nephron Research Matt Larew – William Blair Catherine Schulte – Baird Justin Bowers – Deutsche Bank Sung Ji Nam – Scoti ...

Techne (TECH) came out with quarterly earnings of $0.49 per share, missing the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -3.92%. A quarter ago, it was expected that this maker of medical testing and diagnostic products would post earnings of $0.46 per share when it actually produced earnings of $0.48, delivering a surprise of 4.35%. Over the ...